Combined Diagnostic Efficacy of Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Mean Platelet Volume (MPV) as Biomarkers of Systemic Inflammation in the Diagnosis of Colorectal Cancer.
Journal
Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127
Informations de publication
Date de publication:
2019
2019
Historique:
received:
24
06
2018
revised:
05
11
2018
accepted:
13
11
2018
entrez:
26
2
2019
pubmed:
26
2
2019
medline:
14
6
2019
Statut:
epublish
Résumé
Systemic inflammation in colorectal cancer (CRC) may be reflected by neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and mean platelet volume (MPV). This study was designed to investigate the efficiency of preoperative NLR, PLR, and MVP as a tool for the assessment of tumor characteristics in newly diagnosed patients with CRC. For 300 patients and 300 healthy volunteers, complete blood counts with automated differential counts were performed. The NLR was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count; PLR was calculated by dividing the absolute platelet count by the absolute lymphocyte count. The diagnostic performance of NLR, PLR, and MVP was estimated by ROC curve. ROC curve analysis showed high diagnostic efficacy of NLR and PLR in CRC patients with cut-off values of 2.15 (AUC = 0.790, 95% CI 0.736-0.884, Se = 74.1%, and Sp = 73%) and 123 (AUC = 0.846, 95% CI 0.801-0.891, Se = 73.5%, and Sp = 80%) compared to healthy controls, respectively. The diagnostic efficacy of three combined markers was superior compared with individual markers (AUC = 0.904, 95% CI 0.812-0.989, Se = 96%, and Sp = 70%). NRL, PLR, and MPV may be useful markers in diagnostic and early recognition of different stages of CRC; additionally combined all together have stronger diagnostic efficacy.
Sections du résumé
BACKGROUND
BACKGROUND
Systemic inflammation in colorectal cancer (CRC) may be reflected by neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and mean platelet volume (MPV). This study was designed to investigate the efficiency of preoperative NLR, PLR, and MVP as a tool for the assessment of tumor characteristics in newly diagnosed patients with CRC.
PATIENTS AND METHODS
METHODS
For 300 patients and 300 healthy volunteers, complete blood counts with automated differential counts were performed. The NLR was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count; PLR was calculated by dividing the absolute platelet count by the absolute lymphocyte count. The diagnostic performance of NLR, PLR, and MVP was estimated by ROC curve.
RESULTS
RESULTS
ROC curve analysis showed high diagnostic efficacy of NLR and PLR in CRC patients with cut-off values of 2.15 (AUC = 0.790, 95% CI 0.736-0.884, Se = 74.1%, and Sp = 73%) and 123 (AUC = 0.846, 95% CI 0.801-0.891, Se = 73.5%, and Sp = 80%) compared to healthy controls, respectively. The diagnostic efficacy of three combined markers was superior compared with individual markers (AUC = 0.904, 95% CI 0.812-0.989, Se = 96%, and Sp = 70%).
CONCLUSION
CONCLUSIONS
NRL, PLR, and MPV may be useful markers in diagnostic and early recognition of different stages of CRC; additionally combined all together have stronger diagnostic efficacy.
Identifiants
pubmed: 30800188
doi: 10.1155/2019/6036979
pmc: PMC6360046
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6036979Références
Cancer Res. 1999 Mar 15;59(6):1295-300
pubmed: 10096562
Carcinogenesis. 2000 Mar;21(3):361-70
pubmed: 10688856
Bratisl Lek Listy. 2001;102(1):5-14
pubmed: 11723675
Inflamm Bowel Dis. 2004 Jan;10(1):23-7
pubmed: 15058522
Am J Physiol Gastrointest Liver Physiol. 2004 Jul;287(1):G7-17
pubmed: 15194558
Int J Cancer. 2009 Sep 15;125(6):1298-305
pubmed: 19431213
Exp Mol Med. 2009 Oct 31;41(10):717-27
pubmed: 19561401
Clin Lab Med. 2009 Sep;29(3):523-41
pubmed: 19840685
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Clin Exp Metastasis. 2010 Mar;27(3):141-9
pubmed: 20182908
Arch Pathol Lab Med. 2011 May;135(5):578-87
pubmed: 21526956
CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36
pubmed: 21685461
Biomarkers. 2012 May;17(3):216-22
pubmed: 22424597
Ann Clin Biochem. 2012 May;49(Pt 3):266-72
pubmed: 22492877
Hepatogastroenterology. 2012 Jul-Aug;59(117):1580-2
pubmed: 22683976
Cancer Res. 2012 Aug 15;72(16):3919-27
pubmed: 22751466
Med Oncol. 2013 Mar;30(1):432
pubmed: 23283648
Cancer Lett. 2014 Apr 10;345(2):235-41
pubmed: 23941831
ScientificWorldJournal. 2013 Sep 05;2013:504365
pubmed: 24089602
Int J Cancer. 2014 May 15;134(10):2403-13
pubmed: 24122750
Nat Rev Cancer. 2013 Nov;13(11):759-71
pubmed: 24154716
Chem Immunol Allergy. 2014;99:123-37
pubmed: 24217606
Clin Lab Med. 2013 Dec;33(4):835-59
pubmed: 24267189
J Thorac Dis. 2013 Dec;5(6):783-9
pubmed: 24409356
Semin Oncol. 2014 Jun;41(3):359-69
pubmed: 25023351
World J Gastroenterol. 2014 Aug 7;20(29):9716-31
pubmed: 25110410
Cell Death Dis. 2014 Sep 11;5:e1410
pubmed: 25210793
Eur J Cancer Prev. 2015 Jul;24(4):328-33
pubmed: 25304028
Clin Colorectal Cancer. 2014 Dec;13(4):239-44
pubmed: 25442815
Asian Pac J Cancer Prev. 2014;15(23):10501-4
pubmed: 25556499
World J Gastroenterol. 2016 Apr 7;22(13):3679-86
pubmed: 27053860
PLoS One. 2016 Jul 18;11(7):e0159447
pubmed: 27427969
J Clin Lab Anal. 2017 Sep;31(5):null
pubmed: 27686880
World J Gastrointest Oncol. 2016 Nov 15;8(11):793-800
pubmed: 27895817
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160